Please assess the completion status of the following clinical trial:

Trial Title: A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participant is in good health~* Participant's parent/legal guardian can read, understand, and complete the vaccination report card~* Participant is not sexually active and does not plan on becoming sexually active during the study~* Participant has received a documented full primary immunization series against diphtheria, tetanus, pertussis, and poliovirus (inactivated and/or oral poliovirus), but not in the last 5 years. There must be a 5-year interval from a prior vaccination containing any one of these vaccine antigens.~Exclusion Criteria:~* Participant has a known allergy to any vaccine component of V503 or REPEVAX™~* Participant has had a severe reaction affecting the brain (e.g., evolving encephalopathy) within 7 days after a previous dose of a pertussis-containing vaccine~* Participant has had a progressive severe illness affecting the brain after a previous dose of tetanus, diphtheria, poliovirus or a component pertussis combination (acellular and whole cell) vaccine~* Participant ever had Guillain-Barré syndrome or brachial neuritis following a previous dose of a tetanus-containing vaccine~* Participant has a condition that is a contraindication to vaccination as indicated in the most up to date package inserts of REPEVAX™~* Participant has a history of severe allergic reaction that required medical intervention~* Participant has hemophilia, thrombocytopenia, is receiving anticoagulation therapy and/or has any coagulation disorder that would contraindicate intramuscular injections~* Participant is concurrently enrolled in clinical studies of investigational agents~* Female participant is pregnant~* Participant has donated blood within 1 week prior to first study vaccination, or intends to donate during the study~* Participant is immunocompromised, immunodeficient, or has an autoimmune condition~* Participant has had a splenectomy~* Participant has received immunosuppressive therapies in the prior year~* Participant has received immune globulin product or blood-derived product in the last 3 months~* Participant has received inactivated vaccine(s) within 14 days or live vaccine(s) within 21 days of first study vaccination~* Participant has received a marketed HPV vaccine or has participated in an HPV vaccine trial~* Participant has received a tetanus, diphtheria, pertussis, or poliovirus (inactivated and/or oral poliovirus) vaccination within the last 5 years~* Participant has a fever ≥100°F within 24 hours of vaccination~* Participant has any history or current condition, therapy, lab abnormality, or other circumstance such that it is not in the best interest of the participant to participate~* Participant and parent/legal guardian are unable to give assent/consent~* Participant is unlikely to adhere to the study procedures or is planning to relocate during the study~* Participant has recent history of illicit drug or alcohol abuse~* Participant has a history of HPV

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Concomitant Vaccination (Type: EXPERIMENTAL): V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
- Non-concomitant Vaccination (Type: EXPERIMENTAL): V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1

Based on this trial design, predict the completion outcome and termination type (if applicable).